CLEVELAND, July 13, 2020 /PRNewswire/
-- ViewRay, Inc. (Nasdaq: VRAY) announced today details
relating to the release of its second quarter 2020 financial
results.
ViewRay will hold a conference call to discuss results on
Thursday, July 30, 2020 at
4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844)
277-1426 for domestic callers and (336) 525-7129 for international
callers. The conference ID number is 4968496. A live webcast of the
conference call will be available on the investor relations page of
ViewRay's corporate website at www.investors.viewray.com.
After the live webcast, a replay will remain available online on
the investor relations page of ViewRay's corporate website,
www.investors.viewray.com, for 14 days following the call. In
addition, a telephonic replay of the call will be available until
August 6, 2020. The replay dial-in
numbers are (855) 859-2056 for domestic callers and (404) 537-3406
for international callers. Please use the conference ID number
4968496.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs,
manufactures, and markets the MRIdian® MR-Guided Radiation Therapy
System. MRIdian is built upon a proprietary high-definition MR
imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology.
Unlike MR systems used in diagnostic radiology, MRIdian's
high-definition MR was purpose-built to address specific
challenges, including beam distortion, skin toxicity, and other
concerns that potentially may arise when high magnetic fields
interact with radiation beams. ViewRay and MRIdian are registered
trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Private Securities Litigation Reform Act. Statements in this press
release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, the rate of new orders, upgrades, and installations,
ViewRay's preliminary second quarter results and anticipated future
operating and financial performance, and ViewRay's conference call
to discuss its second quarter 2020 results. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to commercialize MRIdian Linac System, demand for ViewRay's
products, the ability to convert backlog into revenue, the timing
of delivery of ViewRay's products, the timing, length, and severity
of the recent COVID-19 (coronavirus) pandemic, including its
impacts across our businesses on demand, operations and our global
supply chains, the results and other uncertainties associated with
clinical trials, the ability to raise the additional funding needed
to continue to pursue ViewRay's business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, competition in the industry in which
ViewRay operates, and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2019 and its Quarterly Reports on Form 10-Q, as updated
periodically with the company's other filings with the SEC. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-second-quarter-2020-financial-results-to-be-held-after-market-on-july-30-2020-301092012.html
SOURCE ViewRay, Inc.